Skúsenosti s liečbou biosimilárnym infliximabom CT-P13 u pacientov s nešpecifickými zápalovými ochoreniami čreva – retrospektívna štúdia

English version

Autoři: T. Hlavatý ; A. Krajcovicova; I. Sturdik; J. Letkovský; T. Koller; J. Tóth; M. Huorka
Působiště autorů: IBD Center, Subdepartment of Gastroenterology and Hepatology, 5th Department of Internal Medicine, Faculty of Medicine, Comenius University and University Hospital Bratislava, Slovak Republic
Vyšlo v časopise: Gastroent Hepatol 2016; 70(1): 27-36
Kategorie: Původní práce
doi: https://doi.org/10.14735/amgh201627

Souhrn

Úvod:
CT-P13 je prvým schváleným biosimilárom infliximabu. Jeho ekvivalencia s infliximabom bola potvrdená v reumatologických štúdiách avšak skúsenosti s jeho použitím pri liečbe nešpecifických črevných zápalov sú obmedzené.

Cieľ:
Zhodnotiť účinnosť a bezpečnosť liečby CT-P13 u pacientov s nešpecifickými črevnými zápalmi počas prvého roka jeho klinického používania.

Metódy:
Realizovali sme retrospektívnu štúdiu, do ktorej boli zaradení všetci konzekutívni pacienti s Crohnovou chorobou (CD) alebo ulceróznou kolitídou (UC), ktorí boli liečení v období od marca 2014 do apríla 2015 a boli im podané aspoň tri infúzie CT-P13 alebo ukončili liečbu skôr z dôvodu nežiaducej reakcie. Klinická remisia bola zhodnotená v 14. týždni po zahájení indukčnej liečby. U časti pacientov bol CT-P13 zamenený za IFX, ktorý užívali ako udržiavaciu liečbu (switch), v čase zámeny boli všetci v klinickej remisii. Pretrvávajúca klinická odpoveď bola hodnotená každých osem týždňov u pacientov, ktorí zahájili liečbu aj u tých, ktorým bola liečba zamenená.

Výsledky:
Kohorta pozostávala z 25 pacientov s nešpecifickými črevnými zápalmi (19 CD, šesť UC). Spolu bolo podaných 128 infúzií, medián podaných infúzií bol 5 (rozmedzie 2–9) . Trinásť pacientov (deväť CD, štyri UC) dostávalo CT-P13 ako indukčnú liečbu a 84 % (7/ 9 CD, 4/ 4 UC) dosiahlo klinickú remisiu do týždňa 14 a spomedzi tých, čo dosiahli remisiu malo pretrvávajúcu klinickú odpoveď v 30. týždni 85 % (3/ 3 CD, 3/ 4 UC) pacientov. U 12 pacientov (10 CD, dva UC) bol infliximab zmenený na CT-P13, spomedzi nich malo pretrvávajúcu klinickú odpoveď 100 % v 24. týždni, 87,5 % (6/ 7 CD, 1/ 1 UC) v týždni 32 a 75 % (5/ 7 CD, 1/ 1 UC) v týždni 48. U štyroch pacientov s CD bola liečba CT-P13 ukončená pre infúzne reakcie, psoriatiformné kožné lézie a stratu odpovede.

Záver:
Naše skúsenosti naznačujú, že biosimilárny infliximab CT-P13 vykazuje porovnateľnú účinnosť a bezpečnosť ako originálny infliximab.

Kľúčové slová:
Crohnova choroba – ulcerózna kolitída – terapia – infliximab – biosimilár – CT-P13 – retrospektívna štúdia

Autoři deklarují, že v souvislosti s předmětem studie nemají žádné komerční zájmy.

Redakční rada potvrzuje, že rukopis práce splnil ICMJE kritéria pro publikace zasílané do biomedicínských časopisů.

Doručeno:
8. 12. 2015

Přijato:
12. 1. 2016

Zdroje

1. Mowat C, Cole A, Windsor A et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011; 60(5): 571– 607. doi: 10.1136/ gut.2010.224154.

2. Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Eng J Med 1999; 340(18): 1398– 1405.

3. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002; 359(9317): 1541– 1549.

4. Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Eng J Med 2004; 350(9): 876– 885.

5. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Eng J Med 2005; 353(23): 2462– 2476.

6. Hyams J, Crandall W, Kugathasan S et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology 2007; 132(3): 863– 873; quiz 1165– 1166.

7. Burisch J, Vardi H, Pedersen N et al. Costs and resource utilization for diagnosis and treatment during the initial year in a European inflammatory bowel disease inception cohort: an ECCO-EpiCom Study. Inflamm Bowel Dis 2015; 21(1): 121– 131. doi: 10.1097/ MIB.0000000000000250.

8. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Assessment report: Inflectra (infliximab). [online]. Available from: www.ema.europa.eu/ docs/ en_GB/ document_library/ EPAR_-_Public_assessment_report/ human/ 002778/ WC500151490.pdf.

9. Rinaudo-Gaujous M, Paul S, Tedesco EDet al. Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases. Aliment Pharmacol Ther 2013; 38(8): 914– 924. doi: 10.1111/ apt.12477.

10. Hlavaty T, Letkovsky J. Biosimilars in the therapy of inflammatory bowel diseases. Eur J Gastroenterol Hepatol 2014; 26(6): 581– –587. doi: 10.1097/ MEG.0000000000000098.

11. Brodszky V, Baji P, Balogh O et al. Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries. Eur J Health Econ 2014; 15 (Suppl 1): S65– S71. doi: 10.1007/ s10198-014-0595-3.

12. Kim J, Hong JA, Kudrin A. 5 year budget impact analysis of CT-P13 (Infliximab) for the treatment of Crohn’s disease in UK, Italy and France. J Crohns Colitis 2015; 9 (Suppl 1): S144– S145.

13. Schwaber J, Cohen EP. Human x mouse somatic cell hybrid clone secreting immunoglobulins of both parental types. Nature 1973; 244(5416): 444– 447.

14. Yoo DH, Hrycaj P, Miranda P et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013; 72(10): 1613– 1620. doi: 10.1136/ annrheumdis-2012-203090.

15. McKoy JM, Stonecash RE, Cournoyer D et al. Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion 2008; 48(8): 1754– 1762. doi: 10.1111/ j.1537-2995.2008.01749.x.

16. Seidl A, Hainzl O, Richter M et al. Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity. Pharm Res 2012; 29(6): 1454– 1467. doi: 10.1007/ s11095-011-0621-4.

17. Park W, Hrycaj P, Jeka S et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013; 72(10): 1605– 1612. doi: 10.1136/ annrheumdis-2012-203091.

18. Danese S, Gomollon F. Governing Board and Operational Board of ECCO. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohns Colitis 2013; 7(7): 586– 589. doi: 10.1016/ j.crohns.2013.03.011.

19. Gecse KB, Khanna R, van den Brink GRet al. Biosimilars in IBD: hope or expectation? Gut 2013; 62(6): 803– 807. doi: 10.1136/ gutjnl-2012-303824.

20. Silverberg MS, Satsangi J, Ahmad T et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19 (Suppl A): 5A– 36A.

21. Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet 1980; 1(8167): 514.

22. Vermeire S, Schreiber S, Sandborn WJet al. Correlation between the Crohn’s disease activity and Harvey-Bradshaw indices in assessing Crohn’s disease severity. Clin Gastroenterol Hepatol 2010; 8(4): 357– 363. doi: 10.1016/ j.cgh.2010.01.001.

23. Sutherland LR, Martin F, Greer S et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987; 92(6): 1894– 1898.

24. Irvine EJ, Zhou Q, Thompson AK. The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn’s Relapse Prevention Trial. Am J Gastroenterol 1996; 91(8): 1571– 1578.

25. Lewis JD, Chuai S, Nessel L et al. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis 2008; 14(12): 1660– 1666. doi: 10.1002/ ibd.20520.

26. Targan SR, Hanauer SB, van Deventer SJet al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn’s disease. N Eng J Med 1997; 337(15): 1029– 1035.

27. Orlando A, Colombo E, Kohn A et al. Infliximab in the treatment of Crohn’s disease: predictors of response in an Italian multicentric open study. Dig Liver Dis 2005; 37(8): 577– 583.

28. Ricart E, Panaccione R, Loftus EV et al. Infliximab for Crohn’s disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 2001; 96(3): 722– 729.

29. Farrell RJ, Shah SA, Lodhavia PJ et al. Clinical experience with infliximab therapy in 100 patients with Crohn’s disease. Am J Gastroenterol 2000; 95(12): 3490– 3497.

30. Seminerio JL, Loftus EV Jr, Colombel JF et al. Infliximab for Crohn’s disease: the first 500 patients followed up through 2009. Dig Dis Sci 2013; 58(3): 797– 806. doi: 10.1007/ s10620-012-2405-z.

31. Ferrante M, Vermeire S, Katsanos KH et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis 2007; 13(2): 123– 128.

32. Oussalah A, Evesque L, Laharie D et al.A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am J Gastroenterol 2010; 105(12): 2617– 2625. doi: 10.1038/ ajg.2010.345.

33. Gonzalez-Lama Y, Fernandez-Blanco I, Lopez-SanRoman A et al. Open-label infliximab therapy in ulcerative colitis: a multicenter survey of results and predictors of response. Hepatogastroenterology 2008; 55(86– 87): 1609– 1614.

34. Rutgeerts P, D’Haens G, Targan S et al.Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology 1999; 117(4): 761– 769.

35. Armuzzi A, Pugliese D, Danese S et al.Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission. Inflamm Bowel Dis 2013; 19(5): 1065–– 1072. doi: 10.1097/ MIB.0b013e3182802909.

36. Schnitzler F, Fidder H, Ferrante M et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort. Gut 2009; 58(4): 492– 500. doi: 10.1136/ gut. 2008.155812

37. Teshima CW, Thompson A, Dhanoa L et al. Long-term response rates to infliximab therapy for Crohn’s disease in an outpatient cohort. Can J Gastroenterol 2009; 23(5): 348– 352.

38. Kang Y-S, Moon HH, Lee SE et al. Clinical experience of the use of CT-P13, a biosimilar to infliximab in patients with inflammatory bowel disease: a case series. Dig Dis Sci 2015; 60(4): 951– 956. doi: 10.1007/ s10620-014-3392-z.

39. Jung YS, Park DI, Kim YH et al. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study. J Gastroenterol Hepatol 2015. doi: 10.1111/ jgh.12997.

40. Jarzębicka D, Płocek A, Sieczkowska Jet al. First observations of the use of biosimilar infliximab for treatment of ulcerative colitis in paediatric population. J Crohns Colitis 2015; 9 (Suppl 1): S307– S308.

41. Sieczkowska J, Banaszkiewicz A, Płocek Aet al. Assessment of safety and efficacy of biosimilar infliximab in children with Crohn disease: a preliminary report. J Crohns Colitis 2015; 9 (Suppl 1): S295.

42. Jarzębicka D, Banaszkiewicz A, Płocek Aet al. Preliminary assessment of efficacy and safety of switching between originator and biosimilar infliximab in paediatric Crohn disease patients. J Crohns Colitis 2015; 9 (Suppl 1): S224– S225.

43. Gecse K, Farkas K,Lovasz B et al. Biosimilar infliximab in inflammatory bowel diseases: first interim Results from a prospective nationwide observational cohort. J Crohns Colitis 2015; 9 (Suppl 1): S234– S235.